Substituted tetrahydrocarbazole and carbazole carboxamide compounds

US10435415B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Douglas G. Batt · Wilmington, US
• Myra Beaudoin Bertrand · Lambertville, US
• George V. De Lucca · Wilmington, US
• Michael Galella · Kendall Park, US
• Soo S. Ko · Hockessin, US
• Charles M. Langevine · Brooklyn, US
• Qingjie Liu · Newtown, US
• Qing Shi · Princeton, US
• Anurag S. Srivastava · Montgomery, US
• Joseph A. Tino · Lawrenceville, US
• Scott Hunter Watterson · Pennington, US

Key dates

• Filing date: Sep 25, 2018
• Grant date: Oct 8, 2019
• Expiry date: Sep 25, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.